MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lanwpc.2024.101116

Медицинская библиотека · The Lancet regional health. Western Pacific · 2024

Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study.

Hosking Kelly, Binks Paula, De Santis Teresa, Wilson Phillip Merrdi, Gurruwiwi George Garambaka, Bukulatjpi Sarah Mariyalawuy, Vintour-Cesar Emily, McKinnon Melita, Nihill Peter, Fernandes Tammy-Allyn, Greenwood-Smith Belinda, Batey Robert, Ross Cheryl, Tong Steven Y C, Stewart Geoffrey, Marshall Catherine, Gargan Catherine, Manchikanti Prashanti, Fuller Karen, Tate-Baker Jaclyn, Stewart Sami, Cowie Benjamin, Allard Nicole, MacLachlan Jennifer H, Qama Ashleigh, Boettiger David, Davis Joshua S, Connors Christine, Davies Jane, Hep B PAST partnership

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The Northern Territory (NT) has the highest prevalence of chronic hepatitis B (CHB) in Australia. The Hep B PAST program aims to improve health outcomes for people living with CHB.

METHODS

This mixed methods study involves First Nations peoples living in the NT. We used participatory action research principles across three steps: 1. Foundation step: establishing hepatitis B virus (HBV) status and linkage to care; 2. Capacity building: training the health workforce; 3. Supported transition to primary healthcare: implementation of the "Hub and Spoke" model and in-language resources. Analysis occurred at three time points: 1. Pre-Hep B PAST (2018); 2. Foundation step (2020); and 3. Completion of Hep B PAST (2023). Evaluation focuses on four key indicators, the number of people: 1) with documented HBV status; 2) diagnosed with CHB; 3) receiving care; and 4) receiving treatment.

FINDINGS: Hep B PAST (2018-23) reached 40,555 people. HBV status was documented in 11% (1192/10,853), 79.2% (26,075/32,915) and 90.8% (28,675/31,588) of people at pre-Hep B PAST, foundation step, and completion respectively. An estimated 99.9% (821/822) of people were diagnosed, 86.3% (709/822) engaged in care, and 24.1% (198/822) on antiviral treatment at completion. CHB prevalence in the study population is 2.6%, decreasing from 6.1% to 0.4% in the pre- and post-vaccination cohorts.

INTERPRETATION: Hep B PAST is an effective model of care. Partner health services are exceeding elimination targets. This model could enable other countries to enhance the cascade of care and work towards eliminating HBV.

FUNDING: National Health and Medical Research Council.

Для цитирования: Hosking Kelly, Binks Paula, De Santis Teresa, Wilson Phillip Merrdi, Gurruwiwi George Garambaka, Bukulatjpi Sarah Mariyalawuy, Vintour-Cesar Emily, McKinnon Melita, Nihill Peter, Fernandes Tammy-Allyn, Greenwood-Smith Belinda, Batey Robert, Ross Cheryl, Tong Steven Y C, Stewart Geoffrey, Marshall Catherine, Gargan Catherine, Manchikanti Prashanti, Fuller Karen, Tate-Baker Jaclyn, Stewart Sami, Cowie Benjamin, Allard Nicole, MacLachlan Jennifer H, Qama Ashleigh, Boettiger David, Davis Joshua S, Connors Christine, Davies Jane, Hep B PAST partnership. Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study.. The Lancet regional health. Western Pacific. 2024. DOI: 10.1016/j.lanwpc.2024.101116.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.